版本:
中国

OncoMed's lung cancer drug fails mid-stage study

April 17 OncoMed Pharmaceuticals Inc said on Monday its experimental drug failed a mid-stage study for the treatment of lung cancer.

The trial was testing the combination of Oncomed's tarextumab and chemotherapy, compared with chemotherapy and a placebo. The main goal was to slow the progression of the disease.

Last week, the company said it would discontinue a trial testing its experimental drug, demcizumab, as an initial treatment for advanced pancreatic cancer. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D'Silva)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐